Calibrated phase II clinical trials in oncology

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Phase II clinical trials are crucial for evaluating new cancer treatments.
• Traditional designs may be susceptible to unrepresentative patient samples, impacting results.
• The need for robust statistical methods in early-phase oncology research is paramount.

Purpose of the Study:

• To propose and evaluate calibrated designs for phase II oncological clinical trials.
• To assess the statistical properties of calibrated designs, focusing on power recovery and cost-effectiveness.
• To determine the impact of calibrated designs on the reliability of investigational cancer treatment evaluations.

Main Methods:

• Random allocation of patients to investigational or standard treatments (calibration group).
• Utilizing the calibration group to validate the expected response proportion.
• Employing binomial calculations to analyze power recovery and relative cost.
• Recommending a 'master protocol' approach for multiple investigational arms sharing a calibration group.

Main Results:

• Calibrated designs generally recover over 90% of nominal power when unrepresentative samples occur.
• The cost associated with calibrated designs involves a three to fivefold increase in sample size.
• The calibration group serves to flag suspect results from the investigational group, prompting further trials if necessary.

Conclusions:

• Calibrated designs offer a statistically sound approach to enhance the reliability of phase II oncology trials.
• Despite increased sample size, calibrated designs provide significant power recovery, ensuring more dependable treatment evaluations.
• The proposed 'master protocol' approach can optimize resource allocation in multi-arm phase II trials using calibration.